Antigen Activation

Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.

Related Videos
Related Content

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.